Roche puts German investments on hold. RBC keeps CHF 400 target for Roche Holding stock

Published on 10/20/2026 at 09:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sales due October 22, 2026, with RBC 2.7 percent ahead. Roche Holding stock costs EUR 415.58 on October 20, 2026, 0.15 percent below Xetra close.

Roche events and analyst view

Genentech agreed to pay USD 100 million upfront for AL050 on October 5, 2026.
RBC Capital kept its CHF 400.00 Roche target on October 19, 2026.
Roche Holding stock trades at EUR 415.58 at 9:21 a.m. CEST at Lang & Schwarz on October 20, 2026, 0.15 percent below the Xetra close of October 19, 2026.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding (CH1499059983) is reviewing all future investments in Germany after its local chief said on October 19, 2026, that decisions had been put on hold. MarketScreener carried the Reuters report, which also said Roche's planned expansion of more than EUR 600 million in Penzberg was not affected. RBC Capital kept a CHF 400.00 target and an Outperform rating on October 19, 2026.

Germany decision carries a clear limit

The investment review concerns future decisions rather than the planned Penzberg expansion. That distinction gives the announcement a narrower immediate financial impact than a blanket cancellation of German projects.

Roche's latest dated market value is EUR 415.58 at Lang & Schwarz on October 20, 2026 at 9:21 a.m. CEST. The price is EUR 0.62 below the Xetra close of EUR 416.20 on October 19, 2026, a decline of 0.15 percent.

What does RBC see in Roche?

According to Investing.com, RBC's revenue forecast for the third quarter of 2026 was 2.70 percent above consensus. The note also identified giredestrant launch execution as a risk because sampling could weigh on first-year sales.

Three dated Roche events

On October 5, 2026, Genentech, a Roche Group company, agreed to pay USD 100 million upfront for exclusive worldwide rights to Alector's preclinical AL050 program, with up to USD 1.17 billion in milestone payments. Alector disclosed the terms on October 5, 2026. On October 15, 2026, Roche scheduled its third-quarter sales release for 7:00 a.m. CEST on October 22, 2026. On October 19, 2026, Roche put future German investment decisions on hold while leaving the more than EUR 600 million Penzberg expansion unaffected.

Upcoming dates include two tests

Roche will publish third-quarter sales before the Swiss exchange opens on October 22, 2026, followed by a presentation from 2:00 p.m. to 3:30 p.m. CEST. The RBC note also points to a giredestrant regulatory decision on November 30, 2026.

Stock trades below the Xetra close

Roche's German investment review adds political and location risk to a pipeline story that still carries a CHF 400.00 analyst target. The next sales release may clarify whether the 2.70 percent revenue lead cited by RBC is reflected in operating trends.

Roche Holding was trading at EUR 415.58 at Lang & Schwarz on October 20, 2026 at 9:21 a.m. CEST, 0.15 percent below the Xetra close of EUR 416.20 on October 19, 2026. The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.